Comparative Effectiveness of Rheumatoid Arthritis Therapies
- 216 Downloads
Physicians and patients must choose between several therapeutic interventions for rheumatoid arthritis and need to compare the available therapeutic options. Although randomized, placebo-controlled trials are essential to establish the efficacy of a new treatment, they are not much help when it comes to selecting the best therapy for an individual patient. Comparative effectiveness research (CER) is set to provide direct comparisons between therapeutic strategies. CER attempts to weigh the benefits against the potential harms of a particular intervention. Furthermore, CER may help identify specific patient subgroups that are more likely to benefit from a particular therapy or at increased risk of adverse events. Several study designs are available for CER, including pragmatic trials, indirect comparisons using meta-analysis, and observational studies. Understanding the strengths and weaknesses of each design improves the interpretation of the results. In this article, I illustrate CER principles using examples from the literature on biologic antirheumatic agents.
KeywordsRheumatoid arthritis Antirheumatic therapy DMARDs Comparative effectiveness
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.• Schiff M, Keiserman M, Codding C, et al: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096–1103. This is the only large, double-blind, controlled trial that directly compares two competing biologic agents. Infliximab was restricted to 3 mg/kg. The study suggested similar efficacy of infliximab and abatacept but with a better safety profile for the latter.CrossRefPubMedGoogle Scholar
- 11.ClinicalTrials.gov: Switching anti-TNF-alpha agents in RA. Available at http://clinicaltrials.gov/ct2/show/NCT00796705?term=NCT00796705&rank=1. Accessed June 23, 2010.
- 12.ClinicalTrials.gov: Comparison of adalimumab and infliximab treatment of rheumatoid arthritis. Available at http://clinicaltrials.gov/ct2/show/NCT00216177?term=Comparison+of+adalimumab+and+infliximab+treatment+of+rheumatoid+arthritis&rank=1. Accessed June 23, 2010.
- 14.Verstappen SM, Jacobs JW, van der Veen MJ, et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007, 66:1443–1449.CrossRefPubMedGoogle Scholar
- 20.• Singh JA, Christensen R, Wells GA, et al.: A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787–796. This is an “overview of reviews” using indirect comparisons. The results suggest that anakinra is less efficacious than anti-TNF agents or rituximab and that etanercept causes fewer withdrawals due to adverse events than anakinra or monoclonal antibody anti-TNF agents.PubMedGoogle Scholar
- 24.Chen YF, Jobanputra P, Barton P, et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006, 10:iii–iv, xi–xiii, 1–229.Google Scholar
- 34.• Dixon WG, Carmona L, Finckh A, et al.: EULAR points to consider when establishing registers, and when analysing and presenting data. Ann Rheum Dis 2010 Jun 4 (Epub ahead of print). This is a good overview of important points to consider when analyzing an observational study.Google Scholar
- 35.• Mariette X, Tubach F, Bagheri H, et al.: Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69:400–408. This was a population-based observational study on the incidence of lymphoma in RA patients treated with anti-TNF agents. The results suggest a lower risk of lymphoma with use of etanercept than with the monoclonal antibody anti-TNF agents.CrossRefPubMedGoogle Scholar
- 37.• Tubach F, Salmon D, Ravaud P, et al.: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies Registry. Arthritis Rheum 2009, 60:1884–1894. This observational study and that by Dixon et al.  suggest a higher risk of tuberculosis with use of monoclonal antibody anti-TNF agents than with the receptor antagonist etanercept.CrossRefPubMedGoogle Scholar
- 38.• Strangfeld A, Listing J, Herzer P, et al.: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737–744. This was a population-based observational study on the incidence of herpes zoster in RA patients treated with anti-TNF agents. The results suggest a lower risk with use of etanercept than with the monoclonal antibody anti-TNF agents.CrossRefPubMedGoogle Scholar
- 40.Dixon WG, Watson K, Lunt M, et al.: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368–2376.CrossRefPubMedGoogle Scholar
- 42.Finckh A, Dudler J, Wermelinger F, et al.: Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 2010 May 13 (Epub ahead of print).Google Scholar
- 44.• Harrison MJ, Dixon WG, Watson KD, et al.: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68:209–215. This was a large observational study on the incidence of psoriasis in RA patients treated with anti-TNF agents. The results suggest that the incidence of new-onset psoriasis is higher with use of adalimumab than with etanercept or infliximab.CrossRefPubMedGoogle Scholar
- 45.• Hetland ML, Christensen IJ, Tarp U, et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO Registry. Arthritis Rheum 2010, 62:22–32. This was a population-based cohort study about the clinical effectiveness of anti-TNF agents in treatment of RA. The authors found that infliximab had the lowest rates of treatment response, disease remission, and drug adherence of the three agents; adalimumab had the highest rates of treatment response, and etanercept had the longest drug survival rates.CrossRefPubMedGoogle Scholar
- 47.Kristensen LE, Saxne T, Nilsson JA, et al.: Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006, 8:R174.Google Scholar
- 50.Finckh A, Ciurea A, Brulhart L, et al.: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007, 56:1417–1423.CrossRefPubMedGoogle Scholar
- 51.• Finckh A, Ciurea A, Brulhart L, et al.: Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010, 69:387–393. This was an observational study comparing the effectiveness of two competing biologic agents in patient with inadequate response to anti-TNF agents. Rituximab appeared to be superior in patients with a history of resistance to anti-TNF therapy.CrossRefPubMedGoogle Scholar